Decitabin

Decitabin
Klinički podaci
Drugs.com	Monografija
Način primene	Intravenozno
Farmakokinetički podaci
Poluvreme eliminacije	0,5 h
Identifikatori
CAS broj	2353-33-5
ATC kod	None
PubChem	CID 451668
DrugBank	DB01262
ChemSpider	397844
ChEBI	CHEBI:50131
ChEMBL	CHEMBL1201129
Hemijski podaci
Formula	C8H12N4O4
Molarna masa	228,205
	SMILES NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1; ;
	InChI InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1 ; Key:XAUDJQYHKZQPEU-KVQBGUIXSA-N ;

Decitabin je organsko jedinjenje, koje sadrži 8 atoma ugljenika i ima molekulsku masu od 228,205 Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	7
Broj donora vodonika	3
Broj rotacionih veza	2
Particioni koeficijent^[10] (ALogP)	-1,1
Rastvorljivost^[11] (logS, log(mol/L))	-0,2
Polarna površina^[12] (PSA, Å²)	120,7

Reference

^ Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schatzlein A, Twelves C, Kaye SB, Brown R: Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. Appleton, K.; MacKay, H. J.; Judson, I.; Plumb, J. A.; McCormick, C.; Strathdee, G.; Lee, C.; Barrett, S.; Reade, S.; Jadayel, D.; Tang, A.; Bellenger, K.; MacKay, L.; Setanoians, A.; Schätzlein, A.; Twelves, C.; Kaye, S. B.; Brown, R. (2007 Oct 10). . „Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors”. J Clin Oncol. 25 (29): 4603—9. PMID 17925555. doi:10.1200/JCO.2007.10.8688. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Wijermans PW, Ruter B, Baer MR, Slack JL, Hussain SI, Lubbert M: Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res. 2007 Sep 17;. Wijermans, P. W.; Rüter, B.; Baer, M. R.; Slack, J. L.; Saba, H. I.; Lübbert, M. (2008). . „Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)”. Leukemia Research. 32 (4): 587—591. PMID 17881052. doi:10.1016/j.leukres.2007.08.004.
^ Daskalakis M, Blagitko-Dorfs N, Hackanson B: Decitabine. Daskalakis, M.; Blagitko-Dorfs, N.; Hackanson, B. (2010). . „Decitabine”. Recent Results Cancer Res. Recent Results in Cancer Research. 184: 131—57. ISBN 978-3-642-01221-1. PMID 20072836. doi:10.1007/978-3-642-01222-8_10.
^ Saba HI, Wijermans PW: Decitabine in myelodysplastic syndromes. Semin Hematol. 2005 Jul;42(3 Suppl 2):S23-31. Saba, H. I.; Wijermans, P. W. (2005). . „Decitabine in myelodysplastic syndromes”. Seminars in Hematology. 42 (3 Suppl 2): S23—31. PMID 16015501. doi:10.1053/j.seminhematol.2005.05.009.
^ Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H: Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. Jabbour, E.; Issa, J. P.; Garcia-Manero, G.; Kantarjian, H. (2008 Jun). . „Evolution of decitabine development: Accomplishments, ongoing investigations, and future strategies”. Cancer. 112 (11): 2341—51. PMC 4784235 . PMID 18398832. doi:10.1002/cncr.23463. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Stresemann C, Lyko F: Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Stresemann, C.; Lyko, F. (2008 Jul 1). . „Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine”. Int J Cancer. 123 (1): 8—13. PMID 18425818. doi:10.1002/ijc.23607. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Oki Y, Aoki E, Issa JP: Decitabine--bedside to bench. Crit Rev Oncol Hematol. Oki, Y.; Aoki, E.; Issa, J. P. (2007 Feb). . „Decitabine--bedside to bench”. Critical Reviews in Oncology/Hematology. 61 (2): 140—52. PMID 17023173. doi:10.1016/j.critrevonc.2006.07.010. Проверите вредност парамет(а)ра за датум: |date= (помоћ). Epub 2006 Oct 4.
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). . „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). . „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). . „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). . „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). . „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Decitabine

[1] Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schatzlein A, Twelves C, Kaye SB, Brown R: Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. Appleton, K.; MacKay, H. J.; Judson, I.; Plumb, J. A.; McCormick, C.; Strathdee, G.; Lee, C.; Barrett, S.; Reade, S.; Jadayel, D.; Tang, A.; Bellenger, K.; MacKay, L.; Setanoians, A.; Schätzlein, A.; Twelves, C.; Kaye, S. B.; Brown, R. (2007 Oct 10). . „Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors”. J Clin Oncol. 25 (29): 4603—9. PMID 17925555. doi:10.1200/JCO.2007.10.8688. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[2] Wijermans PW, Ruter B, Baer MR, Slack JL, Hussain SI, Lubbert M: Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res. 2007 Sep 17;. Wijermans, P. W.; Rüter, B.; Baer, M. R.; Slack, J. L.; Saba, H. I.; Lübbert, M. (2008). . „Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)”. Leukemia Research. 32 (4): 587—591. PMID 17881052. doi:10.1016/j.leukres.2007.08.004.

[3] Daskalakis M, Blagitko-Dorfs N, Hackanson B: Decitabine. Daskalakis, M.; Blagitko-Dorfs, N.; Hackanson, B. (2010). . „Decitabine”. Recent Results Cancer Res. Recent Results in Cancer Research. 184: 131—57. ISBN 978-3-642-01221-1. PMID 20072836. doi:10.1007/978-3-642-01222-8_10.

[4] Saba HI, Wijermans PW: Decitabine in myelodysplastic syndromes. Semin Hematol. 2005 Jul;42(3 Suppl 2):S23-31. Saba, H. I.; Wijermans, P. W. (2005). . „Decitabine in myelodysplastic syndromes”. Seminars in Hematology. 42 (3 Suppl 2): S23—31. PMID 16015501. doi:10.1053/j.seminhematol.2005.05.009.

[5] Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H: Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. Jabbour, E.; Issa, J. P.; Garcia-Manero, G.; Kantarjian, H. (2008 Jun). . „Evolution of decitabine development: Accomplishments, ongoing investigations, and future strategies”. Cancer. 112 (11): 2341—51. PMC 4784235 . PMID 18398832. doi:10.1002/cncr.23463. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[6] Stresemann C, Lyko F: Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Stresemann, C.; Lyko, F. (2008 Jul 1). . „Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine”. Int J Cancer. 123 (1): 8—13. PMID 18425818. doi:10.1002/ijc.23607. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[7] Oki Y, Aoki E, Issa JP: Decitabine--bedside to bench. Crit Rev Oncol Hematol. Oki, Y.; Aoki, E.; Issa, J. P. (2007 Feb). . „Decitabine--bedside to bench”. Critical Reviews in Oncology/Hematology. 61 (2): 140—52. PMID 17023173. doi:10.1016/j.critrevonc.2006.07.010. Проверите вредност парамет(а)ра за датум: |date= (помоћ). Epub 2006 Oct 4.

[8] Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). . „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[9] Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). . „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[10] Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). . „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.

[11] Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). . „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[12] Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). . „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]